Press releases
- Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results
- Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test
- Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference
- Veracyte Appoints Muna Bhanji to Its Board of Directors
- Veracyte Completes Acquisition of Decipher Biosciences
- Veracyte Commends New USPSTF Lung Cancer Screening Guidelines
- Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference
- Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results
- Veracyte to Present at BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021
More ▼
Key statistics
On Friday, Veracyte Inc (12V:STU) closed at 47.00, -30.88% below its 52-week high of 68.00, set on Feb 10, 2021.
52-week range
Markit short selling activity
Open | 46.60 |
---|---|
High | 47.00 |
Low | 46.60 |
Bid | 40.00 |
Offer | 40.80 |
Previous close | 46.40 |
Average volume | 20.00 |
---|---|
Shares outstanding | 67.00m |
Free float | 64.72m |
P/E (TTM) | -- |
Market cap | 3.23bn USD |
EPS (TTM) | -0.6686 USD |
Data delayed at least 15 minutes, as of Apr 16 2021.
More ▼